Lightpoint Medical Announces Clinical Trial Results of Intraoperative Imaging Technology in Breast Cancer Surgery

CHESHAM, England, December 13, 2016 /PRNewswire/ --

Lightpoint Medical, a medical device company focused on developing innovative imaging technologies to improve cancer surgery, today announced positive clinical trial results for its intraoperative imaging technology in breast cancer surgery. The first-in-human clinical trial showed that intraoperative molecular imaging was a feasible, low-risk, and accurate procedure for assessing tumor margins intraoperatively. The study was conducted by Guy's and St Thomas' Hospital London and published in the Journal of Nuclear Medicine.

     (Photo: http://mma.prnewswire.com/media/448868/PRNE_LightPathProduct_Image.jpg )

Breast-conserving surgery (BCS), also called lumpectomy, is the primary treatment for early-stage breast cancer yet approximately 1 in 4 patients undergoing BCS will need to undergo repeat surgery. Repeat operations are required so frequently because surgeons lack a means to precisely detect the cancer in the initial surgery. Intraoperative molecular imaging potentially provides a means to assess the extent of cancer during surgery and reduce the need for repeat operations.

The study's Principal Investigator, Professor Arnie Purushotham from King's College London and Guy's Hospital, commented: "We're delighted to present these exciting first-in-human results on the use of intraoperative molecular imaging in breast-conserving surgery. This clinical trial showed that molecular imaging agreed strongly with gold standard pathology and was straight-forward to interpret. Although the technology is still in its early days, we believe intraoperative molecular imaging holds considerable promise for improving clinical outcomes in breast cancer patients."

Dr David Tuch, CEO of Lightpoint Medical, said: "These pilot clinical trial results are an important step in Lightpoint Medical's mission to provide clinicians with more accurate tools to guide cancer surgery. We look forward to undertaking further clinical trials to validate these results in larger patient populations."

The LightPath™ Imaging System is CE Marked and approved for sale in the European Union. The clinical trial was supported by funding from Innovate UK, Cancer Research UK King's Health Partners Experimental Cancer Medicine Centre, Guy's and St Thomas' Charity, and the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London.

References

Grootendoorst MR et al. Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery using 18F-FDG Cerenkov Luminescence Imaging - A First-in-Human Feasibility Study. J Nucl Med Published December 8, 2016 as doi:10.2967/jnumed.116.181032

About Lightpoint Medical 

Lightpoint Medical is an innovative medical device company dedicated to improving health outcomes for cancer patients through image-guided surgery. The company's ground-breaking molecular imaging technology has the potential to detect cancer in real-time during surgery and thereby reduce the need for repeat operations. For more information contact [email protected] or visit http://www.lightpointmedical.com

About Innovate UK 

Innovate UK is the UK's innovation agency. It works with people, companies and partner organizations to find and drive the science and technology innovations that will grow the UK economy. For further information visit http://www.innovateuk.gov.uk

SOURCE Lightpoint Medical